Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK
- None.
- None.
Insights
The expansion of Coeptis Therapeutics' license agreement to include autoimmune indications for its SNAP-CAR technology platform marks a significant strategic pivot. This decision not only broadens the application of their cell therapy platforms but also targets a substantial and growing market. The universal CAR T technology, initially focused on oncology, has shown promise in targeting autoreactive B cells, which are implicated in autoimmune diseases. This could potentially disrupt the current treatment paradigms for conditions such as systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis.
The peer-reviewed research supporting the efficacy of CD19-targeting CAR T cells in autoimmune diseases suggests a new therapeutic avenue, leveraging the body's own immune system to combat these diseases. The adaptation of the SNAP-CAR platform to autoimmune diseases could lead to a new class of therapies that are more targeted and potentially more effective than current options. However, it is essential to consider the complexity of autoimmune diseases and the need for extensive clinical trials to establish safety and efficacy in this new context.
The autoimmune disease treatment market is a rapidly expanding sector with a forecasted growth from $7.68 billion in 2024 to $12.64 billion in 2028. Coeptis Therapeutics' move to target this market with its SNAP-CAR technology could position the company to capture a significant share of this growth. The economic implications for Coeptis are substantial, considering the high prevalence of autoimmune diseases and the demographic data indicating that 75% of those affected are women, who may represent a specific target demographic for new treatments.
From an investor's perspective, the expansion into autoimmune disease treatments represents a diversification of Coeptis Therapeutics' portfolio, which could mitigate risk and potentially increase the company's valuation. It's important to monitor the company's progress through clinical trials and regulatory hurdles, as these will be critical in determining the platform's commercial viability and impact on the company's financial performance.
Coeptis Therapeutics' announcement is likely to have a positive impact on its stock valuation due to the potential expansion into a multibillion-dollar market. Investors often respond favorably to biopharmaceutical companies that demonstrate innovation and the ability to address unmet medical needs. The company's commitment to developing treatments for both oncology and autoimmune diseases could be seen as a move to increase its total addressable market, which is a positive signal for growth-oriented investors.
However, the path to market for biopharmaceuticals is fraught with regulatory and developmental challenges. The long-term financial implications will depend on the company's ability to navigate clinical trials and secure regulatory approvals. Investors should consider the inherent risks of drug development, including the possibility of clinical trial failures or delays, which could affect the company's financial health and stock performance.
Exclusive rights to universal CAR technology platform designed to target multiple antigens simultaneously, recently expanded to include SNAP-CAR NK cells, has potential to impact various autoimmune diseases in addition to oncology indications.
Autoimmune diseases, including systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis, are known to result from autoreactive B cells. Recent research, including a paper just published in The New England Journal of Medicine, suggests that CD19-targeting chimeric antigen receptor (CAR) T cells, which have proven to be highly efficient in B cell malignancies, can also target autoreactive B cells that trigger autoimmune diseases.
Research published in the peer-reviewed journal Nature Communications demonstrated the ability of SNAP-CAR to provide a powerful adaptor strategy for fully programmable targeting of engineered cells to multiple antigens, including CD19. Based on these findings, Coeptis Therapeutics plans to expand the development of the SNAP-CAR platform to target the multibillion-dollar autoimmune disease market in addition to hematologic and solid tumors.
"We remain committed to developing these remarkable technologies as treatments for various indications across oncology where there is immense unmet need, however we also recognize the enormous potential for these platform technologies to address and possibly revolutionize the treatment landscape of autoimmune diseases," said Dave Mehalick, President and CEO of Coeptis Therapeutics. "Our SNAP-CAR technologies have the potential to position us at the forefront of next-generation autoimmune directed therapies targeting multiple antigens through combinatorial use of different adaptors."
"We are again excited to expand our license with Coeptis," said Jason Lohmueller, Ph.D., Assistant Professor of Surgery and Immunology in the Division of Surgical Oncology Research, University of
According American Autoimmune Related Disease Association, there are more than 100 autoimmune diseases impacting 1 in every 5 Americans,
About Coeptis Therapeutics Holdings, Inc.
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively "Coeptis"), is a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis' product portfolio and rights are highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. Additionally, Coeptis is developing a universal, multi-antigen CAR T technology licensed from the University of
Cautionary Note Regarding Forward-Looking Statements
This press release and statements of our management made in connection therewith contain or may contain "forward-looking statements" (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). Forward-looking statements include statements concerning our plans, objectives, goals, strategies, future events or performance, and underlying assumptions, and other statements that are other than statements of historical facts. When we use words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, we are making forward-looking statements. Forward-looking statements are not a guarantee of future performance and involve significant risks and uncertainties that may cause the actual results to differ materially and perhaps substantially from our expectations discussed in the forward-looking statements. Factors that may cause such differences include but are not limited to: (1) the inability to maintain the listing of the Company's securities on the Nasdaq Capital Market; (2) the risk that the integration of the Deverra licensed assets will disrupt current plans and operations of the Company; (3) the inability to recognize the anticipated benefits of the newly-licensed assets, which may be affected by, among other things, competition, the ability of the Company to grow and manage growth economically and hire and retain key employees; (4) the risks that the Company's products in development or the newly-licensed assets fail clinical trials or are not approved by the
CONTACTS
Coeptis Therapeutics, Inc.
Andy Galy, Sr. VP of Communications
504-416-6965
andy.galy@coeptistx.com
Tiberend Strategic Advisors, Inc.
Investors
Daniel Kontoh-Boateng
862-213-1398
dboateng@tiberend.com
Media
David Schemelia
609-468-9325
dschemelia@tiberend.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/coeptis-therapeutics-adds-autoimmune-indications-to-exclusive-license-agreement-with-university-of-pittsburgh-for-snap-car-t-and-snap-car-nk-302070740.html
SOURCE Coeptis Therapeutics, Inc.
FAQ
What technology platform did Coeptis Therapeutics Holdings, Inc. recently expand its exclusive license agreement to include autoimmune indications?
What are some autoimmune diseases that Coeptis Therapeutics Holdings, Inc. aims to target with its technology platform?
What is the potential impact of Coeptis Therapeutics Holdings, Inc.'s technology platform on the treatment landscape of autoimmune diseases?
How many Americans are impacted by autoimmune diseases according to the American Autoimmune Related Disease Association?